Article Sidebar
Views pdf: 61
COMPARATIVE DIAGNOSTIC VALUE OF ROMA AND COPENHAGEN INDEX IN POSTMENOPAUSAL WOMEN WITH OVARIAN TUMORS AT THE NATIONAL HOSPITAL OF OBSTETRICS AND GYNECOLOGY
Main Article Content
Abstract
Objective: To describe the clinical and paraclinical characteristics of postmenopausal women with ovarian tumors and to compare the diagnostic performance of the Risk of Ovarian Malignancy Algorithm (ROMA) and the Copenhagen Index (CPH-I) in predicting malignancy. Methods: A cross-sectional descriptive study was conducted on 211 postmenopausal women with ovarian tumors who underwent surgery at the National Hospital of Obstetrics and Gynecology from January 2023 to January 2025. Serum CA-125 and HE4 levels were measured preoperatively to calculate ROMA and CPH-I. Final histopathological results were used as the gold standard to assess diagnostic performance. Results: The mean age was 64.2 ± 8.7 years; 55.4% of patients were asymptomatic. There were 10 cases (4.7%) of ovarian cancer. ROMA showed a sensitivity and specificity of 70.0% and 84.5%, respectively, while CPH-I showed 70.0% and 79.6%. The areas under the ROC curve (AUC) for ROMA and CPH-I were 0.749 and 0.733, respectively. Conclusion: Both ROMA and CPH-I demonstrated reasonable accuracy in predicting malignancy in postmenopausal women with ovarian tumors. ROMA, with higher specificity, is more suitable for use in specialized centers, whereas the simpler CPH-I may be appropriate for primary healthcare settings.
Article Details
Keywords
Ovarian cancer, ROMA, Copenhagen Index, postmenopausal women
References
2. Ovejero-Sánchez M, González-Sarmiento R, Herrero AB. DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities. Cancers. 2023;15(2): 448. doi:10.3390/cancers15020448
3. Bonifácio VDB. Ovarian Cancer Biomarkers: Moving Forward in Early Detection. In: Serpa J, ed. Tumor Microenvironment : The Main Driver of Metabolic Adaptation. Springer International Publishing; 2020:355-363. doi:10.1007/978-3-030-34025-4_18
4. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009; 112(1): 40-46. doi:10.1016/j.ygyno.2008. 08.031
5. Karlsen MA, Høgdall EVS, Christensen IJ, et al. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer — An international multicenter study in women with an ovarian mass. Gynecol Oncol. 2015;138(3):640-646. doi:10.1016/j.ygyno.2015.06.021
6. Trần Doãn Tú, Nguyễn Vũ Quốc Huy. So sánh chỉ số Copenhagen với chỉ số ROMA trong dự báo tiền phẫu ung thư buồng trứng. Tạp Chí Phụ Sản. 2020;18(3): 41-48. doi:10.46755/vjog.2020. 3.1145
7. Nguyễn Hải Phương và cộng sự. Khảo sát chỉ số Copenhagen trên bệnh nhân u buồng trứng tại Bệnh viện Phụ sản Trung ương. Tạp chí Y học Việt Nam. 2023;524(2). doi:10.51298/vmj. v524i2.4874
8. Lê Trung Tín và cộng sự. Giá trị xét nghiệm CA125, HE4 và roma test trong chẩn đoán ung thư buồng trứng tại Bệnh viện Quốc tế Phương Châu. Tạp chí Dược học Cần Thơ. 2023;(69):7-14. doi:10.58490/ctump.2023i69.2110
9. Vo TQN, Tran DT, Nguyen TTN, Vo VD, Le MT, Nguyen VQH. Diagnostic performances of the Ovarian Adnexal Reporting and Data System, the Risk of Ovarian Malignancy Algorithm, and the Copenhagen Index in the preoperative prediction of ovarian cancer: a prospective cohort study. J Gynecol Oncol. 2024;36(2):e30. doi:10.3802/jgo. 2025.36.e30
10. Carreras-Dieguez N, Glickman A, Munmany M, et al. Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors. Diagn Basel Switz. 2022;12(1):226. doi:10.3390/diagnostics12010226